Patheon Announces Appointment of New Chairman of the Board

    TORONTO, July 16 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of
contract development and manufacturing services to the global pharmaceutical
industry, announced today that Peter Green has resigned as Chairman of the
Board and a Director of Patheon Inc. effective yesterday.
    Peter joined the Board in 1996 and has held the position of Chairman
since that time. The Board would like to thank Peter for his 13 years of
service and wishes him well in his future endeavours.
    The Board has appointed Claudio F. Bussandri, who joined the Board in
March 2008, as the Corporation's new Chairman. Mr. Bussandri is the retired
President and CEO of McKesson Canada, a diversified healthcare services
company, where he served from 1995 to 2007. Prior to that, Mr. Bussandri was
President and CEO of Lantic Sugar Limited, a Canadian sugar refiner, from 1987
to 1995. He also served as Executive Chairman of Lantic's U.S. subsidiary,
Refined Sugar Inc. (RSI), and Executive Chairman of Lantic's Barbados sugar
trading company. Mr. Bussandri has also held senior positions at Nabisco
Brands Limited of Canada from 1974 to 1987, including President of the Food
Service Division and held management positions with Gillette of Canada from
1969 to 1974. Currently, Mr. Bussandri is Vice-Chairman of the Board of the
McGill University Health Centre ("MUHC"), and is Chairman of MUHC's Human
Resource Committee. He was previously an Executive Board member and former
Chairman of the Canadian Association for Pharmacy Distribution Management. Mr.
Bussandri received a Bachelor of Engineering (Mechanical) with honours from
McGill University and an M.B.A. from the same university.

    ABOUT PATHEON

    Patheon Inc. (TSX:PTI) is a leading provider of contract development and
manufacturing services to the global pharmaceutical industry. Patheon prides
itself in providing the highest quality products and services to more than 300
of the world's leading pharmaceutical and biotechnology companies. Patheon's
services range from preclinical development through commercial manufacturing
of a full array of dosage forms including parenteral, solid, semi-solid and
liquid forms. Patheon uses many innovative technologies including single-use
disposables, liquid-filled hard capsules and a variety of modified release
technologies.
    Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
    Patheon's integrated development and manufacturing network of 10
facilities, and 7 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
the world.
    %SEDAR: 00001700E

For further information: Mr. Eric Evans, Chief Financial Officer, Tel:
(919) 226-3204, Email: eric.evans@patheon.com; Ms. Doaa A. Fathallah, Senior
Vice President, General Counsel - Europe, Global PDS & Corporate Secretary,
Tel: +41 79 404 3085, Email: doaa.fathallah@patheon.com